Company intelligence / Profile preview

Stereotaxis

St. Louis, Missouri, United Statesstereotaxis.com ↗

Ownership: Public · STXS
Development stage: Commercial

Overview

Stereotaxis has commercialized its Genesis RMN System and related robotic navigation technologies for cardiac ablation. Its systems have been used in over 100,000 patients worldwide. The company recently received FDA clearance for new models and CE mark approval in Europe for its latest products. Clinical use demonstrates improved precision and safety in treating complex arrhythmias with minimally invasive approaches.

Therapeutic areas: Cardiovascular
Modalities: DeviceRobotic systemMedical equipment
Industry: Surgical Medical Devices

Partnerships

Acutus Medical (collaboration on open platform)My Language Connection (translation/localization partner)various hospital networks globally

Financials

Market cap: $127.3M
Total revenue: $7.7M
Enterprise value: $122M

Beyond the preview

Go deeper on Stereotaxis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stereotaxis.

Explore the full profile